Global Orthostatic Hypotension Drugs Market 2022-2026

Global Orthostatic Hypotension Drugs Market 2022-2026

Technavio has been monitoring the orthostatic hypotension drugs market and it is poised to grow by $ 571.76 mn during 2022-2026 progressing at a CAGR of 9.06% during the forecast period. Our report on the orthostatic hypotension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of OH in geriatric population, Increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries.

The orthostatic hypotension drugs market analysis includes the product segment and geographic landscape.

Technavio's orthostatic hypotension drugs market is segmented as below:

By Product

• Midodrine
• Northera (droxidopa)
• Fludrocortisone
• Other drugs

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the research and development of new drugs for OH treatment as one of the prime reasons driving the orthostatic hypotension drugs market growth during the next few years. Also, use of combination therapy in oh treatment and adoption of fludrocortisone as off-label first-line pharmacotherapy will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on orthostatic hypotension drugs market covers the following areas:

• Orthostatic hypotension drugs market sizing
• Orthostatic hypotension drugs market forecast
• Orthostatic hypotension drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orthostatic hypotension drugs market vendors that include Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc. Also, the orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Viatris Inc.